-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2023-509322-22-00
4
2025-11-26
localized colon cancer
-
2024-514538-19-00
5
2025-11-26
Mastocytosis
-
2024-516916-93-00
3
2025-09-08
This study will be a Phase 1b, global, multicenter, open-label, 2-part
-
2024-518135-10-00
5
2024-10-31
Smokers smoking at least 10 cigarettes/day in the past year
-
2024-513576-18-00
5
2020-07-17
Cervical Cancer
-
2023-505084-37-00
7
2025-03-17
Advanced Solid Tumors
-
2024-511030-12-00
3
2025-02-03
Non-small Cell Lung Cancer (NSCLC)
-
2023-503218-56-00
4
2025-01-30
Adult patients with a histologically confirmed TLS-positive advanced o
-
2024-513648-27-00
4
2024-10-25
Patients with newly or active diffuse Systemic sclerosis (SSc) at the
-
2024-516299-13-00
4
2024-09-06
Resectable Gastric Cancer
-
2023-505086-83-00
4
2024-07-10
Tourette Syndrome
-
2023-509001-76-00
5
2024-07-01
Asthma
-
2023-508377-82-00
10
2024-06-27
Hidradenitis Suppurativa (HS)
-
2023-508356-19-00
4
2024-06-25
Pancreatic adenocarcinoma metastatic
-
2023-506823-28-00
4
2024-06-14
Adult patients with locally advanced/metastatic solid tumors
-
2023-509336-25-00
9
2024-06-12
Metastatic castration-resistant prostate cancer
-
2023-505857-42-00
4
2024-04-19
Chronic Kidney Disease, Type 2 diabetes
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2023-505499-32-00
5
2024-03-08
Uncontrolled hypertension (uTHN) defined as blood pressure that remain
-
2022-502461-23-00
5
2024-02-15
Prurigo Nodularis
-
2023-503739-16-00
1
2023-12-20
Relapsed or refractory solid tumors or non-Hodgkin lymphoma
-
2023-503614-80-00
5
2023-12-14
Pulmonary Arterial Hypertension
-
2023-504153-12-00
4
2023-12-07
Advanced or Metastatic Solid Tumors